Astrazeneca (AZN) Current Assets (2016 - 2026)

Astrazeneca has reported Current Assets over the past 17 years, most recently at $29.6 billion for Q1 2026.

For Q1 2026, Current Assets rose 13.29% year-over-year to $29.6 billion; the TTM value through Mar 2026 reached $29.6 billion, up 13.29%, while the annual FY2025 figure was $28.7 billion, 11.21% up from the prior year.
Current Assets for Q1 2026 was $29.6 billion at Astrazeneca, up from $28.7 billion in the prior quarter.
Over five years, Current Assets peaked at $29.9 billion in Q3 2025 and troughed at $20.2 billion in Q3 2022.
A 5-year average of $24.9 billion and a median of $25.1 billion in 2023 define the central range for Current Assets.
On a YoY basis, Current Assets climbed as much as 52.99% in 2022 and fell as far as 24.23% in 2022.
Year by year, Current Assets stood at $22.6 billion in 2022, then rose by 10.89% to $25.1 billion in 2023, then rose by 3.09% to $25.8 billion in 2024, then rose by 11.21% to $28.7 billion in 2025, then rose by 3.1% to $29.6 billion in 2026.
Business Quant data shows Current Assets for AZN at $29.6 billion in Q1 2026, $28.7 billion in Q4 2025, and $29.9 billion in Q3 2025.

Peer Comparison